Analysts call Gilead a takeover target

Will Gilead Sciences continue to stand alone, or will it fall prey to buyout like its neighbors Chiron and Genentech? The company is dominant in the HIV market and is also exploring hear and lung disease treatments. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.